Metabolomics study of dihydrotanshinone Ⅰ on hepatic fibrosis with LC-MS technology
10.12206/j.issn.1006-0111.202101035
- VernacularTitle:基于LC-MS技术的二氢丹参酮Ⅰ抗肝纤维化肝脏代谢组学研究
- Author:
Chaoyang TAO
1
;
Zhenyu ZHU
2
;
Xinrui XING
2
;
Qi CAO
2
;
Hui WANG
2
Author Information
1. Research Center of Pharmaceutical Preparation, Tibet Military General Hospital., Lhasa 8500771, China.
2. Department of Pharmacy, Naval Medical University, Shanghai 200433, China.
- Publication Type:Originalarticles
- Keywords:
hepatic fibrosis;
dihydrotanshinone I;
LC-MS;
metabolomics
- From:
Journal of Pharmaceutical Practice
2021;39(5):403-408
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate therapeutic effects of dihydrotanshinone Ⅰ on hepatic fibrosis based on liver metabolomics method. Methods 28 rats were randomly divided into four groups including control group, hepatic fibrosis model group and dihydrotanshinone Ⅰ low dose group and dihydrotanshinone Ⅰ high dose group. The dihydrotanshinone Ⅰ treated groups received dihydrotanshinone Ⅰ for 28 days. The rat liver samples were collected and analyzed by liquid chromatography-mass spectrometer (LC-MS). The OPLS-DA pattern recognition analysis of metabolomics differences among the groups and therapeutic effects of dihydrotanshinone Ⅰ on hepatic fibrosis were evaluated. Results 38 metabolites were identified through liver metabolomics analysis. The possible mechanism of hepatic fibrosis was mainly involved glutathione metabolism, melatonin metabolism, amino acid metabolism, lipid metabolism and TCA cycle. The hepatic fibrosis induced by TAA was reversed by dihydrotanshinone Ⅰ. Conclusion Dihydrotanshinone Ⅰ provided satisfactory therapeutical effects on hepatic fibrosis through partially regulating the perturbed glutathione metabolism, melatonin metabolism, amino acid metabolism, lipid metabolism, TCA cycle.
